Lori C Jordan1, Adetola A Kassim2, Manus J Donahue2, Meher R Juttukonda2, Sumit Pruthi2, Larry T Davis2, Mark Rodeghier2, Chelsea A Lee2, Niral J Patel2, Michael R DeBaun2. 1. From the Department of Pediatrics, Division of Pediatric Neurology (L.C.J., C.A.L., N.J.P.), Vanderbilt-Meharry Sickle Cell Center for Excellence (A.A.K., M.R.D.), Departments of Radiology and Radiological Sciences (M.J.D., M.R.J.), Neurology (M.J.D.), and Psychiatry (M.J.D.), and Department of Radiology, Divisions of Pediatric Radiology and Neuroradiology (S.P.), and Department of Radiology, Division of Neuroradiology (L.T.D.), Vanderbilt University Medical Center, Nashville; Department of Physics and Astronomy (M.J.D.), Vanderbilt University, Nashville, TN; and Rodeghier Consultants (M.R.), Chicago, IL. lori.jordan@vanderbilt.edu. 2. From the Department of Pediatrics, Division of Pediatric Neurology (L.C.J., C.A.L., N.J.P.), Vanderbilt-Meharry Sickle Cell Center for Excellence (A.A.K., M.R.D.), Departments of Radiology and Radiological Sciences (M.J.D., M.R.J.), Neurology (M.J.D.), and Psychiatry (M.J.D.), and Department of Radiology, Divisions of Pediatric Radiology and Neuroradiology (S.P.), and Department of Radiology, Division of Neuroradiology (L.T.D.), Vanderbilt University Medical Center, Nashville; Department of Physics and Astronomy (M.J.D.), Vanderbilt University, Nashville, TN; and Rodeghier Consultants (M.R.), Chicago, IL.
Abstract
OBJECTIVE: Because of the high prevalence of silent cerebral infarcts (SCIs) in adults with sickle cell anemia (SCA) and lack of information to guide treatment strategies, we evaluated the risk of recurrent SCIs and overt stroke in adults with SCA with preexisting SCI. METHODS: This observational study included adults with SCA (HbSS or Sβ0 thalassemia) aged 18 to 40 years. Participants received 3-tesla brain MRI and a detailed neurologic examination. Time-to-event analysis assessed those with or without baseline SCI and with new or progressive infarcts. The incidence rate of new events was compared by log-rank test. Univariable Cox regression assessed the association of SCI with infarct progression. RESULTS: Among adults with SCA with 2 MRIs and at least 6 months between MRIs (n = 54, mean interval = 2.5 years), 43% had SCI at baseline. Of participants with baseline SCI, 30% had new or progressive SCI over 2.5 years compared to 6% with no SCI at baseline; no participant had an overt stroke. New SCIs at follow-up were present in 12.9 per 100 patient-years with existing SCI compared with 2.4 per 100 patient-years without prior SCI (log-rank test, p = 0.021). No statistically significant differences were seen among those with or without baseline SCI in use of hydroxyurea therapy, hydroxyurea dose, or other stroke risk factors. The presence of SCI was associated with increased hazard of a new or progressive infarct (hazard ratio 5.27, 95% confidence interval 1.09-25.51, p = 0.039). CONCLUSIONS: Silent infarcts in adults with SCA are common and are a significant risk factor for future silent infarcts.
OBJECTIVE: Because of the high prevalence of silent cerebral infarcts (SCIs) in adults with sickle cell anemia (SCA) and lack of information to guide treatment strategies, we evaluated the risk of recurrent SCIs and overt stroke in adults with SCA with preexisting SCI. METHODS: This observational study included adults with SCA (HbSS or Sβ0 thalassemia) aged 18 to 40 years. Participants received 3-tesla brain MRI and a detailed neurologic examination. Time-to-event analysis assessed those with or without baseline SCI and with new or progressive infarcts. The incidence rate of new events was compared by log-rank test. Univariable Cox regression assessed the association of SCI with infarct progression. RESULTS: Among adults with SCA with 2 MRIs and at least 6 months between MRIs (n = 54, mean interval = 2.5 years), 43% had SCI at baseline. Of participants with baseline SCI, 30% had new or progressive SCI over 2.5 years compared to 6% with no SCI at baseline; no participant had an overt stroke. New SCIs at follow-up were present in 12.9 per 100 patient-years with existing SCI compared with 2.4 per 100 patient-years without prior SCI (log-rank test, p = 0.021). No statistically significant differences were seen among those with or without baseline SCI in use of hydroxyurea therapy, hydroxyurea dose, or other stroke risk factors. The presence of SCI was associated with increased hazard of a new or progressive infarct (hazard ratio 5.27, 95% confidence interval 1.09-25.51, p = 0.039). CONCLUSIONS: Silent infarcts in adults with SCA are common and are a significant risk factor for future silent infarcts.
Authors: Allison A King; John J Strouse; Mark J Rodeghier; Bruce E Compas; James F Casella; Robert C McKinstry; Michael J Noetzel; Charles T Quinn; Rebecca Ichord; Michael M Dowling; J Philip Miller; Michael R Debaun Journal: Am J Hematol Date: 2014-02 Impact factor: 10.047
Authors: Michael R DeBaun; Mae Gordon; Robert C McKinstry; Michael J Noetzel; Desiree A White; Sharada A Sarnaik; Emily R Meier; Thomas H Howard; Suvankar Majumdar; Baba P D Inusa; Paul T Telfer; Melanie Kirby-Allen; Timothy L McCavit; Annie Kamdem; Gladstone Airewele; Gerald M Woods; Brian Berman; Julie A Panepinto; Beng R Fuh; Janet L Kwiatkowski; Allison A King; Jason M Fixler; Melissa M Rhodes; Alexis A Thompson; Mark E Heiny; Rupa C Redding-Lallinger; Fenella J Kirkham; Natalia Dixon; Corina E Gonzalez; Karen A Kalinyak; Charles T Quinn; John J Strouse; J Philip Miller; Harold Lehmann; Michael A Kraut; William S Ball; Deborah Hirtz; James F Casella Journal: N Engl J Med Date: 2014-08-21 Impact factor: 91.245
Authors: Adetola A Kassim; Sumit Pruthi; Matthew Day; Mark Rodeghier; Melissa C Gindville; Max A Brodsky; Michael R DeBaun; Lori C Jordan Journal: Blood Date: 2016-03-03 Impact factor: 22.113
Authors: S T Miller; E A Macklin; C H Pegelow; T R Kinney; L A Sleeper; J A Bello; L D DeWitt; D M Gallagher; L Guarini; F G Moser; K Ohene-Frempong; N Sanchez; E P Vichinsky; W C Wang; D L Wethers; D P Younkin; R A Zimmerman; M R DeBaun Journal: J Pediatr Date: 2001-09 Impact factor: 4.406
Authors: K Ohene-Frempong; S J Weiner; L A Sleeper; S T Miller; S Embury; J W Moohr; D L Wethers; C H Pegelow; F M Gill Journal: Blood Date: 1998-01-01 Impact factor: 22.113
Authors: N Valadi; G S Silva; L S Bowman; D Ramsingh; P Vicari; A C Filho; A R Massaro; A Kutlar; F T Nichols; R J Adams Journal: Neurology Date: 2006-08-22 Impact factor: 9.910
Authors: R J Adams; V C McKie; L Hsu; B Files; E Vichinsky; C Pegelow; M Abboud; D Gallagher; A Kutlar; F T Nichols; D R Bonds; D Brambilla Journal: N Engl J Med Date: 1998-07-02 Impact factor: 91.245
Authors: Paolo Rigano; Lucia De Franceschi; Laura Sainati; Antonio Piga; Frédéric B Piel; Maria Domenica Cappellini; Carmelo Fidone; Nicoletta Masera; Giovanni Palazzi; Barbara Gianesin; Gian Luca Forni Journal: Blood Cells Mol Dis Date: 2017-10-09 Impact factor: 3.039
Authors: Meher R Juttukonda; Manus J Donahue; Spencer L Waddle; Larry T Davis; Chelsea A Lee; Niral J Patel; Sumit Pruthi; Adetola A Kassim; Lori C Jordan Journal: J Cereb Blood Flow Metab Date: 2020-04-11 Impact factor: 6.200
Authors: Grace Champlin; Scott N Hwang; Andrew Heitzer; Juan Ding; Lisa Jacola; Jeremie H Estepp; Winfred Wang; Kenneth I Ataga; Curtis L Owens; Justin Newman; Allison A King; Robert Davis; Guolian Kang; Jane S Hankins Journal: Exp Biol Med (Maywood) Date: 2021-08-18
Authors: Seung Yup Lee; Rowan O Brothers; Katherine B Turrentine; Ayesha Quadri; Eashani Sathialingam; Kyle R Cowdrick; Scott Gillespie; Shasha Bai; Adam E Goldman-Yassen; Clinton H Joiner; R Clark Brown; Erin M Buckley Journal: Front Neurol Date: 2022-07-01 Impact factor: 4.086
Authors: Yan Wang; Kristin P Guilliams; Melanie E Fields; Slim Fellah; Michael M Binkley; Martin Reis; Katie D Vo; Yasheng Chen; Chunwei Ying; Morey Blinder; Allison A King; Monica L Hulbert; Hongyu An; Jin-Moo Lee; Andria L Ford Journal: Stroke Date: 2022-05-12 Impact factor: 10.170
Authors: Skylar E Johnson; Colin D McKnight; Lori C Jordan; Daniel O Claassen; Spencer Waddle; Chelsea Lee; Maria Garza; Niral J Patel; L Taylor Davis; Sumit Pruthi; Paula Trujillo; Rohan Chitale; Matthew Fusco; Manus J Donahue Journal: J Cereb Blood Flow Metab Date: 2021-04-28 Impact factor: 6.200
Authors: M R DeBaun; L C Jordan; A A King; J Schatz; E Vichinsky; C K Fox; R C McKinstry; P Telfer; M A Kraut; L Daraz; F J Kirkham; M H Murad Journal: Blood Adv Date: 2020-04-28
Authors: Lena Václavů; Jan Petr; Esben Thade Petersen; Henri J M M Mutsaerts; Charles B L Majoie; John C Wood; Ed VanBavel; Aart J Nederveen; Bart J Biemond Journal: Am J Hematol Date: 2020-01-28 Impact factor: 13.265